GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immutep Ltd (ASX:IMM) » Definitions » Cyclically Adjusted Price-to-FCF

Immutep (ASX:IMM) Cyclically Adjusted Price-to-FCF : (As of Jun. 04, 2025)


View and export this data going back to 1988. Start your Free Trial

What is Immutep Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Immutep Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Immutep's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immutep Cyclically Adjusted Price-to-FCF Chart

Immutep Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Immutep Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Immutep's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Immutep's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immutep's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immutep's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Immutep's Cyclically Adjusted Price-to-FCF falls into.


;
;

Immutep Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Immutep's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2024 is calculated as:

For example, Immutep's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.014/129.4637*129.4637
=-0.014

Current CPI (Dec. 2024) = 129.4637.

Immutep Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
200906 0.000 86.278 0.000
201006 0.000 88.971 0.000
201106 0.000 92.129 0.000
201206 0.000 93.244 0.000
201212 0.000 94.730 0.000
201306 0.000 95.473 0.000
201312 0.000 97.330 0.000
201406 0.000 98.352 0.000
201412 0.000 99.002 0.000
201506 0.000 99.838 0.000
201512 0.000 100.673 0.000
201603 0.000 100.488 0.000
201606 0.000 100.859 0.000
201612 0.000 102.159 0.000
201703 0.000 102.624 0.000
201706 0.000 102.809 0.000
201712 0.000 104.110 0.000
201806 0.000 104.945 0.000
201812 0.000 105.967 0.000
201906 0.000 106.617 0.000
201912 0.000 107.917 0.000
202006 0.000 106.246 0.000
202009 0.000 107.917 0.000
202012 -0.017 108.846 -0.020
202103 0.000 109.496 0.000
202106 -0.029 110.332 -0.034
202109 -0.007 111.168 -0.008
202112 -0.008 112.654 -0.009
202203 -0.013 115.069 -0.015
202206 -0.009 117.112 -0.010
202209 -0.007 119.248 -0.008
202212 -0.006 121.477 -0.006
202303 -0.016 123.148 -0.017
202306 -0.009 124.170 -0.009
202309 -0.011 125.656 -0.011
202312 -0.005 126.399 -0.005
202403 -0.008 127.606 -0.008
202406 -0.006 128.906 -0.006
202409 -0.006 129.185 -0.006
202412 -0.014 129.464 -0.014

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Immutep  (ASX:IMM) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Immutep Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Immutep's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Immutep Business Description

Industry
Traded in Other Exchanges
Address
264 George Street, Level 32, Australia Square, Sydney, NSW, AUS, 2000
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.

Immutep Headlines

No Headlines